Published on

Toxicology: Terfenadine

DESCRIPTION

Terfenadine, previously marketed under the brand name Seldane, is a second-generation histamine H1-receptor antagonist that produces minimal sedative effects.

FORMS AND USES

The usual adult oral dose was 60 mg. Terfenadine was withdrawn from the United States pharmaceutical market in 1997 because of concerns regarding serious cardiac adverse effects.

TOXIC DOSE

The unchanged parent compound, terfenadine, is primarily responsible for its toxic effects. Its metabolites exhibit substantially lower toxicity. Toxicity may develop when the parent drug accumulates because of impaired metabolism or excessive ingestion.

PATHOPHYSIOLOGY

Terfenadine toxicity is associated with potentially life-threatening ventricular arrhythmias, particularly torsades de pointes. These complications may arise when terfenadine is administered alongside medications that inhibit hepatic cytochrome P450 enzymes, resulting in reduced drug metabolism and increased circulating concentrations of the parent compound.

EPIDEMIOLOGY

Cases of torsades de pointes associated with terfenadine have been documented under several circumstances, including intentional overdose, consumption of doses exceeding therapeutic recommendations, underlying hepatic cirrhosis, a history of excessive alcohol consumption, and concurrent administration of contraindicated medications.

CAUSES

Most reported cases of terfenadine poisoning result from interactions with other medications that interfere with its metabolism.

In infants younger than one year, possible neglect or nonaccidental poisoning should be considered when clinically appropriate. In children older than six years, intentional self-poisoning should also be assessed as a potential cause.

DRUG AND DISEASE INTERACTIONS

Several medications can increase the risk of terfenadine toxicity by inhibiting its hepatic metabolism and promoting accumulation of the parent drug.

Important interacting agents include ketoconazole, itraconazole, metronidazole, fluconazole, miconazole, and macrolide antibiotics such as erythromycin.

Underlying hepatic disease may further impair terfenadine clearance and increase susceptibility to adverse cardiovascular effects.

DIAGNOSIS

An accurate diagnosis depends on obtaining a comprehensive medical and medication history, with particular attention to recently administered or concurrently used drugs.

Because pharmacokinetic interactions are a major cause of terfenadine toxicity, identifying medications that inhibit hepatic drug metabolism is especially important.

DIFFERENTIAL DIAGNOSIS

Terfenadine poisoning should be considered in patients presenting with otherwise unexplained syncope, seizure-like episodes, ventricular tachyarrhythmias, or QTc prolongation on electrocardiography.

Other causes of these manifestations should also be evaluated during the diagnostic assessment.

SIGNS AND SYMPTOMS

Cardiovascular Manifestations

Cardiovascular toxicity is the principal concern in terfenadine poisoning. Clinical findings may include syncope, ventricular tachyarrhythmias, QTc interval prolongation, and torsades de pointes.

Seizure-like activity may occur in association with significant cardiac rhythm disturbances and reduced cerebral perfusion.

Neurological Manifestations

Neurological symptoms may include dizziness, lightheadedness, and transient loss of consciousness. These manifestations are often secondary to cardiovascular instability rather than direct neurological toxicity.

PROCEDURES AND LABORATORY TESTS

Essential Investigations

Serum electrolytes: Electrolyte measurements are necessary to identify abnormalities that may contribute to cardiac arrhythmias or episodes of syncope.

Complete blood count: This investigation may help identify additional conditions contributing to the patient’s presentation.

Renal function tests: Blood urea nitrogen (BUN) and serum creatinine should be assessed as part of the evaluation of possible causes of syncope and associated medical complications.

Electrocardiography and cardiac monitoring: A 12-lead ECG and continuous cardiac monitoring are essential for detecting QTc prolongation and ventricular rhythm disturbances.

Toxicological screening: In suspected overdose, serum acetaminophen and salicylate concentrations should be measured to identify possible unrecognized coingestions.

TREATMENT

Management of terfenadine poisoning primarily involves supportive care, with particular emphasis on cardiovascular stabilization.

Prompt recognition and treatment of ventricular tachyarrhythmias are essential to reduce the risk of serious complications.

DIRECTING PATIENT COURSE

Consultation With a Poison Control Center

Specialist toxicology advice should be obtained when poisoning produces severe or persistent clinical manifestations.

Consultation is also indicated when concurrent drug ingestion, clinically significant drug interactions, or preexisting medical disorders complicate patient management.

Referral to a Healthcare Facility

Hospital evaluation is warranted when intentional self-harm or deliberate poisoning by another person is suspected.

Patients should also be referred for medical assessment if toxic manifestations develop or when coingested substances, medication interactions, or underlying illnesses create additional clinical concerns.

Admission Considerations

Patients who develop syncope or demonstrate QTc prolongation on electrocardiography require admission to a monitored setting, potentially an intensive care unit.

The historical source recommends continuous ECG monitoring until at least 24 hours after symptoms have resolved and the QTc interval has returned to baseline.

DECONTAMINATION

Out-of-Hospital Management

Inducing vomiting with ipecac syrup is not recommended because of the potential risks associated with this intervention.

In-Hospital Management

For substantial ingestions occurring within the preceding few hours, the historical source describes a single dose of activated charcoal at 1–2 g/kg without an accompanying cathartic.

The suitability of gastrointestinal decontamination should be determined according to current toxicology recommendations, including the time since ingestion and the patient’s airway status.

ANTIDOTES

No specific antidote is available for terfenadine poisoning. Treatment is therefore directed toward supportive care, monitoring, and correction of potentially life-threatening complications.

ADJUNCTIVE TREATMENT

Intravenous magnesium sulfate has been used successfully in managing terfenadine-associated torsades de pointes.

Additional interventions may include isoproterenol administration, electrical cardioversion, or temporary cardiac pacing, depending on the type of arrhythmia and the patient’s cardiovascular condition.

These treatments require specialist supervision and should follow current cardiac resuscitation and toxicology protocols.

FOLLOW-UP

Patient Monitoring

Patients with suspected terfenadine toxicity should undergo electrocardiographic evaluation and continuous cardiac monitoring when clinically indicated.

Particular attention should be given to changes in the QTc interval and the development of ventricular arrhythmias.

Expected Course and Prognosis

Complete recovery is generally expected when significant complications are promptly recognized and treated.

However, prolonged hypotension and its associated consequences may adversely affect clinical outcomes.

DISCHARGE

Discharge Criteria and Instructions

The historical guidance indicates that patients who remain asymptomatic and demonstrate normal ECG findings may be considered for discharge after appropriate decontamination and an observation period of at least six hours.

Psychiatric evaluation may be necessary when intentional ingestion or self-harm is suspected.

Actual discharge decisions should be based on current clinical guidance, the circumstances of exposure, and the patient’s overall condition.

PITFALLS AND PRECAUTIONS

Terfenadine should not be administered concurrently with medications that inhibit its metabolism, particularly ketoconazole, itraconazole, metronidazole, fluconazole, miconazole, and macrolide antibiotics such as erythromycin.

Concomitant use with medications capable of prolonging the QTc interval or inducing torsades de pointes should also be avoided. Examples include quinidine, procainamide, disopyramide, sotalol, haloperidol, thioridazine, probucol, and pentamidine.

Terfenadine should additionally be avoided in individuals with congenital long QT syndrome because of the increased risk of serious ventricular arrhythmias.

ICD-9-CM CLASSIFICATION

963.0 — Poisoning by systemic agents, specifically antiallergic and antiemetic medications.

RELATED TOPIC

Ventricular dysrhythmias.


Image description
0 Comments